• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20073 / 2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

25 April 2007/in 2007, AT7519 – CDK inhibitor, Products

2007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-04-25 14:12:422016-11-25 14:13:062007_Comparison of AT7519 in Solid Tumor and Hematological Cell Lines

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Supergen Sells Select Non-Core Assets to Intas Link to: Supergen Sells Select Non-Core Assets to Intas Supergen Sells Select Non-Core Assets to Intas Link to: SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 Link to: SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470 SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP4...
Scroll to top Scroll to top Scroll to top